Loading decisions…
Loading decisions…
644 vetted Board decisions in 2026.
The Board has remanded the claims of service connection for prostate cancer, gastroesophageal reflux disease (GERD), diabetes mellitus (DM), and rhinitis due to potential toxic exposure during service. The Veteran's reported jet fuel/fume exposure will be addressed in a TERA examination.
The Board denied the Veteran's claim for an initial compensable rating for residuals from prostate cancer, finding that his prostate cancer was in remission and did not result in any renal dysfunction, voiding dysfunction, or functional impact.
The Veteran's prostate cancer, diabetes mellitus, type II, and hypertension claims are remanded due to the need for additional development regarding participation in toxic exposure risk activities (TERA) during service.
The Board has determined that the Veteran's prostate cancer is not related to his service, including any exposure to asbestos or other carcinogens. The evidence does not support a finding of service connection for prostate cancer.
The Board denied the Veteran's request to restore a 100 percent disability rating for prostate cancer and his claim for an increased disability rating for prostate cancer residuals with voiding dysfunction.
The Veteran's service connection claim for prostate cancer was denied as there is no credible evidence of herbicide exposure during his active duty in Korea, and the condition did not manifest within one year of separation. The Board found that the current diagnosis is unrelated to any in-service injury or event.
The Veteran's status post prostate cancer is rated at a 40 percent rating from November 6, 2017, to February 9, 2024. A higher rating is denied.
The Veteran's appeal of a reduction from 100% to 40% disability rating for prostate cancer with urinary incontinence is dismissed due to the Veteran's death.
The Board has determined that the Veteran's prostate cancer is related to service and grants service connection for this condition.
The Veteran's claims for prostate cancer, Diabetes Mellitus type 2 (DM), and right upper extremity neuropathy have been granted as they are presumed to be related to herbicide exposure during service.,Service connection is established for the Veteran's prostate cancer, DM, and right upper extremity neuropathy due to their presumptive association with herbicide agent exposure.
The Veteran's service-connected disabilities do not meet the criteria for additional SMC under levels L through O.
The Veteran's claims for service connection for prostate cancer, hypertension, and left ankle ankylosis have been denied as there is no evidence of a qualifying additional disability due to VA care or treatment.
The Veteran's prostate cancer is being remanded for a medical opinion to determine if it is related to his service exposure to toxins in Germany.
The Veteran's appeal was dismissed due to his death during the pendency of the appeal.
The Veteran's prostate cancer is granted as service connected due to exposure to contaminated water at Camp Lejeune during his military service.
The Board has determined that a remand is needed to correct a pre-decisional duty to assist error, specifically regarding the need for regular aid and attendance on a substitution basis. The case will be returned to the AOJ for further action.
The Board has granted service connection for hypertension and prostate cancer, finding that exposure to contaminated water at Camp Le Jeune led directly to the development of these conditions.
The Board has denied the Veteran's claims for service connection for prostate cancer, ischemic heart disease, and hypertension, finding that there is no evidence of a direct relationship to his military service or exposure to herbicides.
The Veteran's appeal for a higher rating for prostate cancer and an earlier effective date for loss of use of the right foot has been denied. The Veteran is already receiving the maximum schedular rating for prostate cancer, which was granted in December 2023. The effective date for service connection for loss of use of the right foot was set at January 22, 2023.
The Board has decided that the Veteran is eligible to receive past-due benefits awarded in a February 6, 2025 rating decision. However, due to an error in not documenting these past-due benefits, the case is being remanded for further action.
← Back to Prostate cancer overview
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.